drugset / Trial / NCT06753955
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG
Timeline
- Start
- 2025-02-25
- Primary completion
- 2025-07-02
- Completion
- 2025-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ART5803 | Protein / enzyme biologic | — | Intravenous |
| Background | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | Intravenous |